Table 1 Clinicopathological characteristics in responders and non-responders.
From: Multicentre biomarker cohort study on the efficacy of nivolumab treatment for gastric cancer
Responder (n = 25) | Non-responder (n = 118) | Response rate (%) | P value | ||
|---|---|---|---|---|---|
Age (years) | <70 | 8 | 51 | 13.6 | 0.30 |
≥70 | 17 | 67 | 20.2 | ||
Sex | Male | 19 | 91 | 17.3 | 0.90 |
Female | 6 | 27 | 18.2 | ||
Performance status | 0–1 | 25 | 98 | 20.3 | 0.026 |
2–3 | 0 | 20 | 0.0 | ||
BMI (kg/m2) | <20 | 11 | 57 | 16.2 | 0.70 |
≥20 | 14 | 61 | 18.7 | ||
Histology* | Differentiated | 16 | 77 | 17.2 | 0.89 |
Undifferentiated | 8 | 41 | 16.3 | ||
History of gastrectomy | Yes | 18 | 66 | 21.4 | 0.14 |
No | 7 | 52 | 11.9 | ||
Number of previous chemotherapy regimens | 2 | 14 | 66 | 17.5 | 0.64 |
3 | 6 | 36 | 14.3 | ||
≥4 | 5 | 16 | 23.8 | ||
Liver metastasis | Yes | 7 | 49 | 12.5 | 0.21 |
No | 18 | 69 | 20.7 | ||
Lung metastasis | Yes | 2 | 10 | 16.7 | 0.94 |
No | 23 | 108 | 17.6 | ||
Lymph node metastasis | Yes | 16 | 63 | 20.3 | 0.33 |
No | 9 | 55 | 14.1 | ||
Peritoneum metastasis | Yes | 3 | 42 | 6.7 | 0.021 |
No | 22 | 76 | 22.4 | ||
NLR | <2.4 | 11 | 58 | 15.9 | 0.64 |
≥2.4 | 14 | 60 | 18.9 | ||
CRP (mg/dL)* | <1.0 | 21 | 78 | 21.2 | 0.087 |
≥1.0 | 4 | 39 | 9.3 | ||
PD-L1 TPS | <1 | 14 | 94 | 13.0 | 0.012 |
≥1 | 11 | 24 | 31.4 | ||
PD-L1 CPS | <1 | 6 | 49 | 10.9 | 0.10 |
≥1 | 19 | 69 | 21.6 | ||
PD-L1 CPS | <5 | 10 | 81 | 11.0 | 0.007 |
≥5 | 15 | 37 | 28.8 | ||
PD-L1 CPS | <10 | 12 | 99 | 10.8 | <0.001 |
≥10 | 13 | 19 | 40.6 | ||
MMR | Proficient | 15 | 107 | 12.3 | <0.001 |
Deficient | 10 | 11 | 47.6 |
